ROCKVILLE, Md. (PRWEB) October 26, 2017
Immunaccel introduces its Scheduled Assay and Build an Assay programs to streamline the manner in which clients can access in vitro and in vivo immune-oncology assays. Immunaccel offers it’s “tool box” of proprietary paired T cell and tumor lines, patient derived samples, assays and model systems to design assays that accelerate immuno-oncology research and development efforts.
As the scientific dialogue in immuno-oncology shifts towards understanding immunotherapy resistance, immune cell interactions and tumor environments, Immunaccel aims to provide the right “tools” for partners to address these key areas of research and development.
The Scheduled Assays program is a cost-effective approach for partners to generate first line validation datasets. Immunaccel will develop and publish a monthly schedule of assays using its “tool box”. Partners can reserve selected assays slots for the most relevant testing schema for their drug candidates. Based on a pre-defined schedule, clients will receive defined readouts and data sets for their drug candidates(s).
Also launching today is Immunaccel’s Build an Assay program that empowers clients to customize assays using Immunaccel’s “tool box” of key biological resources. The Build an Assay program offers a simple online submission form that allows partners to select cell lines and readouts based on their product development strategies. Using this approach, partners can tailor immune-oncology assays that enable unique and specific product testing criteria that best suit their I/O product strategies.
“In a highly competitive field like immuno-oncology, we recognize that our partners may have constraints on budgets, timelines and changing product development strategies" said Vik Subbu, Chief Executive Officer of Immunaccel. "By opening our “tool box” we help partners access and design assays that accelerate answers for their programs” he added.